Global Acute Migraine Drugs Market Size, Key Players and Drug Type: Ergot Alkaloids, Analgesics, Triptans, Others

Acute migraine is a neurological disorder characterized by severe headaches, nausea, and sensitivity to light and sound. The global acute migraine drugs market includes a variety of pharmaceutical products used to treat and prevent migraine attacks.

Get a Free Sample Copy of the Global Acute Migraine Drugs Market Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=6848987

The global Acute Migraine Drugs market was worth USD 8.40 billion in 2021 and is anticipated to expand at a CAGR of 7.82% between 2023 and 2028. The rising prevalence of migraine among the working population, as well as increasing healthcare expenditure, are driving up demand for acute migraine medications.

Triptans are widely used migraine medications because they are selective serotonin receptor agonists. They work by increasing serotonin levels in the brain, which reduces inflammation and constricts blood vessels, thereby ending the headache or migraine. Triptans account for approximately 46% of the overall market share by drug type segment in 2021. For Mild pain treatment of Migraine, over-the-counter medications such as Naproxen, Ibuprofen, Aspirin, Acetaminophen, Pseudoephedrine, or phenylephrine are widely utilized.

Some of the key players in the global acute migraine drugs market include:

AbbVie Inc.
Allergan plc
Amgen Inc.
Eli Lilly and Company
GlaxoSmithKline plc
Johnson & Johnson
Novartis AG
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.

The global acute migraine drugs market has been growing in recent years, driven by the increasing prevalence of migraine worldwide and the introduction of new and innovative drug therapies. In addition, the development of targeted therapies that address specific pathways involved in migraine pathophysiology is expected to further drive market growth in the coming years.

Direct Purchase of the Global Acute Migraine Drugs Market Research Report at https://www.reportsnreports.com/purchase.aspx?name=6848987

However, the market is also facing challenges such as competition from generics, regulatory hurdles, and the high cost of new and innovative therapies. In addition, the COVID-19 pandemic has had a significant impact on the healthcare industry, including the acute migraine drugs market, due to disruptions in supply chains, clinical trials, and healthcare delivery.

+ 1 347 333 3771
sales@reportsandreports.com

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.

This release was published on openPR.